|Bid||13.87 x 1000|
|Ask||14.11 x 1000|
|Day's range||12.94 - 14.90|
|52-week range||10.81 - 21.25|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.47|
Every investor in Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) should be aware of the most powerful shareholder...
Futures on the Nasdaq Composite (NASDAQINDEX: ^IXIC) were all over the map in premarket trading Friday morning, as many investors reacted negatively to bad news from athletic footwear and apparel giant Nike in its most recent quarterly financial report. Nike's premarket losses of 13% were extreme, but it turns out that there were two Nasdaq stocks with even bigger declines early Friday. Both Intercept Pharmaceuticals (NASDAQ: ICPT) and Rent-A-Center (NASDAQ: RCII) posted steeper drops as they tried to work through some major setbacks and reassure their shareholders that the future could improve.
Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE studyMORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that REVERSE, a Phase 3 study evaluating the safety and effi